Merck & Co

News

AZ/Merck & Co's Lynparza delays spread of pancreatic cancer

AstraZeneca and Merck & Co’s Lynparza could offer a new option for certain patients with pancreatic cancer after a trial showed it slowed progression of the disease.

News

Merck's Keytruda gets boost in kidney and head and neck canc...

Merck & Co and its cancer immunotherapy Keytruda has gained a double boost in its tussle with rival Bristol-Myers Squibb, with positive results in kidney cancer, and the promise of an F

News

FDA accepts Merck & Co's two new antibacterial drug applicat...

The FDA has accepted two new antibacterial drug applications from Merck & Co, both of which have received Priority Review.

News

FDA approves Samsung/Merck & Co's Herceptin biosimilar

The FDA has approved a new biosimilar of Roche’s breast cancer drug Herceptin, from Samsung Bioepis and Merck & Co, ahead of the original drug’s US patent expiry in June.

News

FDA extends review of Merck & Co's Keytruda in lung cancer u...

US regulators have pushed back the deadline for their review of Merck & Co’s immunotherapy Keytruda in certain patients with untreated lung cancer, after the pharmaceutical company subm

News

AZ/Merck & Co get new US use for ovarian cancer drug

After several disappointments this year AstraZeneca has ended 2018 on a positive note, gaining a new use for its ovarian cancer drug Lynparza in the US and a first approval in China for its

AZ/Merck & Co's Lynparza delays spread of pancreatic cancer

Merck's Keytruda gets boost in kidney and head and neck canc...

FDA accepts Merck & Co's two new antibacterial drug applicat...

FDA approves Samsung/Merck & Co's Herceptin biosimilar

FDA extends review of Merck & Co's Keytruda in lung cancer u...

AZ/Merck & Co get new US use for ovarian cancer drug

ASH: AstraZeneca's dual-wielding CAR-T shows promise

How to meet your physicians where they are online

Merck &amp; Co

Editor's Picks

Merck & Co